Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia

Diagnostic Pathology

Volumn 10, Issue 1, 2015, Pages

  Liu, Li ^a   Chen, Ren'an ^a   Zhang, Yangping ^a   Fan, Wen ^a   Xiao, Fang ^a   Yan, Xueqian ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Circulating; miR 328; Prognosis

Indexed keywords

HEMOGLOBIN; MICRORNA; MIRN328 MICRORNA, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; METABOLISM; MIDDLE AGED; MORTALITY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; THROMBOCYTE COUNT; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; HEMOGLOBINS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; MICRORNAS; MIDDLE AGED; PLATELET COUNT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937205222     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/s13000-015-0345-6     Document Type: Article

References (31)

1. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484-95. doi: 10.1016/S0140-6736(12)61727-9.
2. Meyer SC, Levine RL. Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 2014;15(9):e382-94. doi: 10.1016/S1470-2045(14)70008-7.
3. Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol. 2009;2:23. doi: 10.1186/1756-8722-2-23.
4. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-54.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
6. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-8. doi: 10.1038/nature03702.
7. Takada S, Yamashita Y, Berezikov E, Hatanaka H, Fujiwara SI, Kurashina K, et al. MicroRNA expression profiles of human leukemias. Leukemia. 2008;22(6):1274-8. doi: 10.1038/sj.leu.2405031.
8. Babashah S, Sadeghizadeh M, Tavirani MR, Farivar S, Soleimani M. Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell Oncol (Dordr). 2012;35(5):317-34. doi: 10.1007/s13402-012-0095-3.
9. Sun SM, Rockova V, Bullinger L, Dijkstra MK, Dohner H, Lowenberg B, et al. The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. Leukemia. 2013;27(1):100-6. doi: 10.1038/leu.2012.158.
10. Chen XX, Lin J, Qian J, Qian W, Yang J, Ma JC, et al. Dysregulation of miR-124-1 predicts favorable prognosis in acute myeloid leukemia. Clin Biochem. 2014;47(1-2):63-6. doi: 10.1016/j.clinbiochem.2013.09.020.
11. Li Z, Huang H, Li Y, Jiang X, Chen P, Arnovitz S, et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 2012;119(10):2314-24. doi: 10.1182/blood-2011-10-386235.
12. Li Y, Lin J, Yang J, Qian J, Qian W, Yao DM, et al. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia. Leuk Res. 2013;37(12):1642-7. doi: 10.1016/j.leukres.2013.09.022.
13. Qu H, Xu W, Huang Y, Yang S. Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev. 2011;12(5):1117-25.
14. Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One. 2011;6(6), e20769. doi: 10.1371/journal.pone.0020769.
15. Cheng G. Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2015;81C:75-93. doi: 10.1016/j.addr.2014.09.001.
16. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010;140(5):652-65. doi: 10.1016/j.cell.2010.01.007.
17. Wu Z, Sun L, Wang H, Yao J, Jiang C, Xu W, et al. MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma. PLoS One. 2012;7(10), e47270. doi: 10.1371/journal.pone.0047270.
18. Ulivi P, Foschi G, Mengozzi M, Scarpi E, Silvestrini R, Amadori D, et al. Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC. Int J Mol Sci. 2013;14(5):10332-42. doi: 10.3390/ijms140510332.
19. He F, Lv P, Zhao X, Wang X, Ma X, Meng W, et al. Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction. Mol Cell Biochem. 2014;394(1-2):137-44. doi: 10.1007/s11010-014-2089-0.
20. Swerdllow S, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. France: IARC Press. 2008;2008.
21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-5.
22. Lo Coco F, Foa R. Diagnostic and prognostic advances in the immunophenotypic and genetic characterization of acute leukaemia. Eur J Haematol. 1995;55(1):1-9.
23. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-83.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. doi: 10.1006/meth.2001.1262.
25. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-8.
26. Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol. 2014;24(16):R762-76. doi: 10.1016/j.cub.2014.06.043.
27. Yu J, Wang Y, Dong R, Huang X, Ding S, Qiu H. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J Cancer Res Clin Oncol. 2012;138(4):671-4. doi: 10.1007/s00432-012-1147-9.
28. Xin SY, Feng XS, Zhou LQ, Sun JJ, Gao XL, Yao GL. Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis. World J Gastroenterol. 2014;20(22):6906-11. doi: 10.3748/wjg.v20.i22.6906.
29. Fayyad-Kazan H, Bitar N, Najar M, Lewalle P, Fayyad-Kazan M, Badran R, et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med. 2013;11:31. doi: 10.1186/1479-5876-11-31.
30. Yuan J, Zheng Z, Zheng Y, Lu X, Xu L, Lin L. microRNA-328 is a favorable prognostic marker in human glioma via suppressing invasive and proliferative phenotypes of malignant cells. Int J Neurosci. 2015:1-22. doi: 10.3109/00207454.2014.1002610.
31. Chen CH, Cheng CY, Chen YC, Sue YM, Liu CT, Cheng TH, et al. MicroRNA-328 inhibits renal tubular cell epithelial-to-mesenchymal transition by targeting the CD44 in pressure-induced renal fibrosis. PLoS One. 2014;9(6), e99802. doi: 10.1371/journal.pone.0099802.